Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$1.17 - $2.49 $639 - $1,362
547 New
547 $0
Q2 2022

Aug 03, 2022

SELL
$3.38 - $5.27 $682 - $1,064
-202 Closed
0 $0
Q1 2022

May 02, 2022

SELL
$4.76 - $6.24 $633 - $829
-133 Reduced 39.7%
202 $0
Q4 2021

Feb 23, 2022

BUY
$5.7 - $9.1 $1,909 - $3,048
335 New
335 $2,000
Q2 2021

Aug 12, 2021

SELL
$7.6 - $10.28 $12,258 - $16,581
-1,613 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$9.81 - $13.88 $14,204 - $20,098
1,448 Added 877.58%
1,613 $16,000
Q4 2020

Feb 02, 2021

SELL
$9.47 - $12.43 $1,250 - $1,640
-132 Reduced 44.44%
165 $1,000
Q3 2020

Oct 14, 2020

SELL
$8.15 - $21.17 $12,811 - $33,279
-1,572 Reduced 84.11%
297 $2,000
Q2 2020

Jul 13, 2020

BUY
$21.19 - $40.2 $13,879 - $26,331
655 Added 53.95%
1,869 $40,000
Q1 2020

Apr 29, 2020

SELL
$32.32 - $58.37 $517 - $933
-16 Reduced 1.3%
1,214 $45,000
Q4 2019

Feb 05, 2020

BUY
$25.0 - $92.22 $30,750 - $113,430
1,230 New
1,230 $69,000

Others Institutions Holding NXTC

About NextCure, Inc.


  • Ticker NXTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,748,800
  • Market Cap $36.4M
  • Description
  • NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...
More about NXTC
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.